TLSI
TriSalus Life Sciences, Inc.
NASDAQ · USHealthcareMedical - Devices
$4.31+0.47%
Price as of Jul 20, 2026
TLSI financials
TriSalus Life Sciences, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $45.2M | $29.4M | $18.5M | $12.4M |
| Cost of revenue | $7.0M | $4.1M | $2.6M | $2.3M |
| Gross profit | $38.2M | $25.3M | $15.9M | $10.1M |
| Operating expenses | $65.1M | $61.5M | $70.4M | $46.6M |
| Operating income | -$26.9M | -$36.2M | -$54.5M | -$36.4M |
| Net income | -$39.2M | -$33.2M | -$59.4M | -$47.2M |
| EBITDA | -$33.0M | -$32.4M | -$58.7M | -$46.8M |
| Basic EPS | $-1.84 | $-1.25 | $-2.23 | $-1.59 |
| Diluted EPS | $-1.84 | $-1.25 | $-2.23 | $-1.59 |
| Balance sheet | ||||
| Cash & equivalents | $20.4M | $8.5M | $11.8M | $9.4M |
| Total assets | $35.3M | $24.0M | $24.6M | $22.0M |
| Total liabilities | $69.2M | $49.9M | $51.7M | $34.3M |
| Stockholders’ equity | -$33.9M | -$25.9M | -$27.1M | -$12.3M |
| Total debt | $34.4M | $23.6M | $1.6M | $2.0M |
| Net debt | $14.0M | $15.1M | -$10.2M | -$7.5M |
| Cash flow | ||||
| Operating cash flow | -$18.0M | -$40.8M | -$50.6M | -$32.3M |
| Capital expenditure | -$918.0K | -$345.0K | -$588.0K | -$786.0K |
| Free cash flow | -$18.9M | -$41.2M | -$51.2M | -$33.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |